U.S. Semiconductors Stock News

NYSEAM:KULR
NYSEAM:KULRElectrical

Defense Drone Battery Prototype Deal Could Be A Game Changer For KULR Technology Group (KULR)

KULR Technology Group recently announced it entered into a prototype development and fabrication agreement with a U.S.-based defense drone manufacturer to design, test, and qualify lithium-ion battery packs for unmanned aerial vehicles and handheld controllers, while also advancing next-generation drone battery pack integration using Factorial Inc.’s solid-state and lithium-metal cells. Together, these collaborations deepen KULR’s role in mission-critical unmanned systems by pairing its KULR...
NYSE:RKT
NYSE:RKTDiversified Financial

Is It Time To Reassess Rocket Companies (RKT) After Recent Share Price Pullback?

If you are wondering whether Rocket Companies stock is priced attractively today, the starting point is understanding how its current share price lines up against several valuation checks. The stock closed at US$12.94, with the share price down 9.3% over the past week, 7.6% over the past month and 34.9% year to date, while still showing a 3.8% gain over the last year and a 59.7% gain over three years, but down 32.3% over five years. Recent coverage around Rocket Companies has focused on its...
NasdaqGS:BKNG
NasdaqGS:BKNGHospitality

Is It Time To Reassess Booking Holdings (BKNG) After This Year’s Share Price Slide

If you are wondering whether Booking Holdings at around US$164.78 is attractively priced or not, the key is understanding what the current share price actually reflects about its long term prospects. The stock is down 2.1% over the past week, 0.5% over the past month, 22.6% year to date and 25.3% over the last year, even though the 3 year and 5 year returns sit at 58.7% and 81.3% respectively. These moves have come as investors reassess many travel related stocks, with attention on how...
NYSE:KVYO
NYSE:KVYOSoftware

Why Klaviyo (KVYO) Is Up 10.4% After Raising 2026 Guidance And Launching A $500 Million Buyback

Klaviyo recently reported strong Q1 2026 results, with 28% year-over-year revenue growth, its best operating margin since listing, a larger customer base of more than 196,000 accounts, and a newly authorized US$500.00 million share repurchase program. The company also raised its full-year 2026 revenue guidance while emphasizing deeper AI integration across its platform, underscoring management’s focus on AI-enabled expansion and capital returns even as it prepares for a CFO transition later...
NasdaqGS:FLYW
NasdaqGS:FLYWDiversified Financial

Is It Too Late To Consider Flywire (FLYW) After A 46% One Year Gain?

Wondering if Flywire's current share price around US$14.61 still leaves room for value, or if most of the upside is already priced in. The stock is down 7.6% over the past week but up 2.7% over the last month, 5.1% year to date, and 46.1% over the past year, which can change how you think about both its potential and its risk. These moves come after a period where investors have been reassessing high growth payment and financial technology stocks. There has been attention on business models...
NasdaqGS:ANAB
NasdaqGS:ANABBiotechs

AnaptysBio Shifts Fiscal Year-End As Volatile Stock Eyes Growth Forecasts

AnaptysBio (NasdaqGS:ANAB) has approved a change in its fiscal year-end from December 31 to June 30. The new fiscal year-end is expected to affect the timing of future financial reports and corporate disclosures. The decision reflects an adjustment to the company’s reporting calendar and financial planning framework. AnaptysBio, trading at $51.24, has recorded very large share price gains over the past year, with the stock up 261.4% over that period and 220.2% over five years. The...
NYSE:SF
NYSE:SFCapital Markets

Is Stifel Financial (SF) Offering Value After Recent Pullback And Capital Markets Headlines

Wondering if Stifel Financial, at a recent US$69.37 share price, is offering value or just noise? This article breaks down what that price could mean for you. The stock is down 1.8% over the past week and 9.2% over the past month, even though the 1 year return sits at 13.4% and the 3 year and 5 year returns are 83.9% and 76.5% respectively. Recent headlines around capital markets activity and the broader financial sector have kept investor attention on firms such as Stifel Financial. This...
NasdaqGM:VCYT
NasdaqGM:VCYTBiotechs

Veracyte (VCYT) Is Up 9.4% After New Phase III Data Validates Prosigna Chemotherapy-Guidance Role – Has The Bull Case Changed?

Veracyte has recently reported strong Phase III clinical data for its Prosigna Breast and Decipher Prostate genomic tests at ASCO 2026 and confirmed the upcoming U.S. commercial launch of Prosigna on June 8, 2026 for early-stage hormone-receptor positive breast cancer patients. The new evidence suggests these tests can help oncologists tailor chemotherapy use more precisely, potentially sparing many high-risk breast and prostate cancer patients from unnecessary treatment and its long-term...
NYSE:RTX
NYSE:RTXAerospace & Defense

Is RTX (RTX) Still Fairly Priced After Recent Share Price Pullback?

If you are wondering whether RTX at around US$172.55 a share offers fair value or is starting to look stretched, the valuation picture is the key place to focus. RTX's share price has pulled back slightly in the short term, declining 2.3% over the last week and 0.2% over the last month, and is also down 7.9% year to date, even though it is still up 26.5% over 1 year, 86.5% over 3 years and 116.8% over 5 years. These mixed returns arrive as investors continue to weigh broader defense and...
NYSE:YUM
NYSE:YUMHospitality

Will Yum! Brands’ (YUM) COO Transition and New Roles Redefine Its Culture and Franchise Strategy?

Yum! Brands has announced that longtime Chief Operating Officer and Chief People & Culture Officer Tracy Skeans will retire, with her transitioning from her current roles on November 1, 2026, into a Senior Advisor position until March 1, 2028. Her planned retirement marks the departure of a key architect of Yum!’s franchising model and culture, prompting a multi‑year leadership transition as the company recruits a new Chief People & Culture Officer and a new Chief Scale Officer. With this...
NYSE:NUVB
NYSE:NUVBPharmaceuticals

A Look At Nuvation Bio (NUVB) Valuation After New IBTROZI Outcomes And Regulatory Progress

Nuvation Bio (NUVB) is back in focus after reporting new patient-reported outcomes from its pivotal TRUST-II study of IBTROZI in advanced ROS1+ non small cell lung cancer, alongside fresh regulatory milestones. See our latest analysis for Nuvation Bio. The recent TRUST-II data and regulatory updates arrive after a mixed share price pattern, with a 30 day share price return of 7.03% and a year to date share price decline of 44.99%, while the 1 year total shareholder return is 92.65% and the 3...
NasdaqGS:CTSH
NasdaqGS:CTSHIT

Cognizant Deepens AI And Security Ties As Valuation Lags Targets

Cognizant Technology Solutions (NasdaqGS:CTSH) expanded its AI collaboration with Snowflake to deploy AI-powered intelligent agents at scale across industries. The companies aim to help enterprises adopt AI more quickly, with a focus on AI-driven business workflows and measurable operational outcomes. Cognizant also broadened its alliance with CrowdStrike to address security and governance needs tied to large-scale AI deployments. Cognizant sits at the intersection of IT services, cloud...
NasdaqCM:LPTH
NasdaqCM:LPTHElectronic

LightPath Raises US$50m Equity For Growth While Dilution Weighs On Holders

LightPath Technologies (NasdaqCM:LPTH) has completed a follow-on equity offering via a registered direct deal. The company raised gross proceeds of US$50 million. Management plans to use the new capital for working capital, investments, acquisitions, and other corporate purposes. LightPath Technologies focuses on photonics solutions, supplying optical components and related products into areas where demand for high precision optics has been growing across multiple applications. This fresh...
NasdaqGS:XP
NasdaqGS:XPCapital Markets

Is XP (XP) Looking Attractive After Recent Share Price Pullback?

If you are wondering whether XP at around US$15.60 is starting to look like a bargain or still carries too much risk, the recent share performance gives you some important clues. The stock has fallen about 9% over the past week, around 15.7% over the past month, and is down 19.5% over the past year. This may change how investors think about both its potential and its risks. Recent coverage of XP has focused on how the stock has pulled back over different timeframes and what that says about...
NasdaqGM:BLBD
NasdaqGM:BLBDMachinery

Is It Too Late To Consider Blue Bird (BLBD) After Its 85% One Year Surge?

Some investors may be wondering whether Blue Bird's share price still offers value after a strong run, or if most of the opportunity has already been priced in. The stock last closed at US$72.43, with returns of 2.2% over 7 days, 15.2% over 30 days, 54.9% year to date and 85.6% over the past year. Recent coverage has focused on how this long term share price performance has sharpened the market's focus on what Blue Bird might be worth compared with its current price. Investors are watching...
NYSE:SO
NYSE:SOElectric Utilities

Southern Highlights Grid Upgrades As New Corporate Affairs Leader Steps In

Georgia Power, a subsidiary of Southern Company (NYSE:SO), appointed Anthony Oni as vice president of Corporate Affairs. The company also highlighted significant investments in grid upgrades as the Atlantic hurricane season begins. The announcement links a leadership change with operational preparations for severe weather events affecting Georgia Power's service territory. Southern, through Georgia Power, operates in a sector where reliability and storm readiness are core to the business...
NasdaqGS:CNXC
NasdaqGS:CNXCProfessional Services

Does Concentrix (CNXC) Becoming an AI CX Partner Reshape Its Long‑Term Competitive Narrative?

In recent days, Concentrix has been recognized on the Fortune 500 list for the third consecutive year, advanced its AI-powered iX and agentic platforms, and reported revenue and profitability in line with guidance while continuing to manage debt and invest in growth. Together, these developments highlight how Concentrix is positioning itself as an AI-focused customer experience partner at a time when enterprises are rethinking how people, technology, and automation work together. Next, we’ll...
NYSE:GNL
NYSE:GNLREITs

Assessing Global Net Lease (GNL) Valuation After Recent Share Price Softness And Income Focus

Why Global Net Lease is on investors’ radar today Global Net Lease (GNL) has been drawing fresh attention after recent trading left the stock at a last close of US$9.21, prompting investors to reassess its income focused real estate footprint. See our latest analysis for Global Net Lease. The share price has eased in recent sessions, with a 1-day share price return of a 1.50% decline and a 7-day share price return of a 2.85% decline. However, the 1-year total shareholder return of 33.29% and...
NasdaqGM:BZAI
NasdaqGM:BZAISemiconductor

Assessing Blaize Holdings (BZAI) Valuation After COMPUTEX 2026 Collaboration With Winmate

Blaize Holdings (BZAI) is in focus after its joint presence with Winmate at COMPUTEX 2026 in Taipei, where the companies are showing rugged edge AI systems built around Blaize’s GSP-based AI acceleration. See our latest analysis for Blaize Holdings. Despite the COMPUTEX spotlight and partnerships around edge AI, Blaize Holdings’ share price has been volatile, with a 90-day share price return of 52.99% but a 1-year total shareholder return that declined 27.82%. This indicates short term...
NasdaqGS:CRDO
NasdaqGS:CRDOSemiconductor

Is It Too Late To Consider Credo Technology Group Holding (CRDO) After 180.7% One Year Surge?

Wondering if Credo Technology Group Holding is priced for more upside or already reflects the buzz around it? This article focuses squarely on what the current share price might be implying. The stock last closed at US$214.60, after a 19.2% gain over the past 30 days and a 49.8% return year to date. Over the last 7 days it saw a 3.0% decline, and the 1 year return sits at 180.7% with a very large 3 year gain. These moves have put Credo on many investors' radars, especially given the strong 1...
NYSE:TJX
NYSE:TJXSpecialty Retail

TJX Companies’ Best Buddies Role Highlights Brand And Culture Investment

TJX Companies (NYSE:TJX) served as headline sponsor of the 27th Annual Best Buddies Challenge. The event raised over US$4m to support people with intellectual and developmental disabilities. This philanthropic effort highlights TJX Companies' focus on community engagement and social responsibility. TJX Companies, the off price retailer behind brands like T.J. Maxx and Marshalls, is known primarily for its value focused apparel and home goods offering. This large scale support of the Best...
NYSE:BYD
NYSE:BYDHospitality

Boyd Gaming Expansions Test Growth Story After Flat Q1 Results

Boyd Gaming (NYSE:BYD) is moving ahead with several major property projects, including the new Cadence Crossing Casino in Las Vegas. The company is progressing a large resort development in Virginia that is planned as a key addition to its regional portfolio. Regulators have approved a significant expansion at Boyd’s Illinois property, clearing the way for further build out. For you as an investor, these projects matter because they show how Boyd Gaming is allocating capital across core...
NasdaqGS:ZD
NasdaqGS:ZDInteractive Media and Services

Assessing Ziff Davis (ZD) Valuation After Q1 Earnings Miss And Accelerated Buybacks

Ziff Davis (ZD) just reported Q1 results with lower revenue and adjusted EBITDA, weighed down by Tech & Shopping, while management pushed ahead with asset sales, share repurchases, and greater use of AI across its portfolio. See our latest analysis for Ziff Davis. At a share price of US$44.54, Ziff Davis has given shareholders a 31.04% year to date share price return and a 36.25% total shareholder return over one year. However, the 3 year and 5 year total shareholder returns are down 33.70%...
NasdaqGS:BBIO
NasdaqGS:BBIOBiotechs

How FDA Priority Review for First-in-Class LGMD Drug BBP-418 Could Impact BridgeBio Pharma (BBIO) Investors

BridgeBio Pharma announced that the FDA previously accepted and granted Priority Review to its New Drug Application for oral BBP-418 in LGMD2I/R9, setting a PDUFA target action date of November 27, 2026, without planning an advisory committee meeting. If approved, BBP-418 would be the first therapy for LGMD2I/R9 and any limb-girdle muscular dystrophy, potentially qualifying BridgeBio for a Priority Review Voucher and opening up further rare disease development paths. We’ll now examine how...